Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quinagolide - Ferring Pharmaceuticals/Novartis

Drug Profile

Quinagolide - Ferring Pharmaceuticals/Novartis

Alternative Names: CV 205 502; FE-999051; Norprolac; Quinagolide hydrochloride; SDS-205502; SDZ-205502

Latest Information Update: 05 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Ferring Pharmaceuticals; Novartis
  • Class Aminoquinolines; Analgesics; Infertility therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility; Hyperprolactinaemia; Prolactinoma
  • Phase II Endometriosis; Pain

Most Recent Events

  • 21 Jun 2019 Phase-II clinical trials in Endometriosis in Denmark (Vaginal) (NCT03749109)
  • 28 Nov 2018 Phase-II clinical trials in Pain in USA (Vaginal) (NCT03692403)
  • 27 Nov 2018 Ferring Pharmaceuticals plans the QLARITY phase II trial for Endometriosis in Denmark, Germany and Spain (NCT03749109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top